As drug production rapidly becomes more complex, medical and drug benefit teams within payer organizations need to get aligned with the latest evidence.
New drug approvals from the US Food and Drug Administration (FDA) hit an all-time high in 2023 and specialty drugs now account for 54% of claims spending. Medications are becoming more complex and developing more rapidly, underscoring the need for regular health plan policy development and design.